Spots Global Cancer Trial Database for chronic myelogenous leukemia
Every month we try and update this database with for chronic myelogenous leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS | NCT00334074 | Acute Myelogeno... Myelodysplastic... Chronic Myeloge... | Clofarabine and... | 18 Years - 85 Years | Baylor Research Institute | |
| Repeat Dose Safety Study for Compound to Treat Hematologic Cancer | NCT00881946 | Hematologic Mal... | GSK21110183 | 18 Years - | Accenture | |
| Repeat Dose Safety Study for Compound to Treat Hematologic Cancer | NCT00881946 | Hematologic Mal... | GSK21110183 | 18 Years - | Accenture | |
| Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer | NCT00723099 | Acute Lymphobla... Acute Myeloid L... Aggressive Non-... Chronic Myeloge... Chronic Phase C... Indolent Non-Ho... Lymphoma Mixed Phenotype... Myelodysplastic... Myeloproliferat... Recurrent Chron... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Plasm... Recurrent Small... Recurrent T-Cel... Refractory Chro... Refractory Chro... Refractory Foll... Refractory Hodg... Refractory Lymp... Refractory Mant... Refractory Smal... T-Cell Non-Hodg... | Allogeneic Hema... Cyclophosphamid... Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Total-Body Irra... Umbilical Cord ... | - 69 Years | Fred Hutchinson Cancer Center | |
| Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies | NCT02639559 | Acute Myelogeno... Acute Lymphobla... Chronic Myeloge... Non-Hodgkin's L... Non-Hodgkin Lym... Hodgkin Disease Hodgkins Diseas... Hodgkin's Disea... Multiple Myelom... Myelodysplastic... Myeloproliferat... | BL-8040 Leukapheresis Hematopoietic c... | 18 Years - 75 Years | Washington University School of Medicine | |
| WT1 for the Detection of Minimal Residual Disease | NCT00179829 | Leukemia Cancer | WT 1 Testing | - 21 Years | Ann & Robert H Lurie Children's Hospital of Chicago | |
| Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies | NCT00270881 | Acute Myelogeno... Acute Lymphobla... Chronic Myeloge... Myelodysplastic... | Cord blood tran... TBI cyclophosphamid... cytarabine | 20 Years - 55 Years | Keio University | |
| Cognitive Behavioral Intervention for Targeted Therapy Fatigue (CBT-TTF) Intervention | NCT02592447 | Chronic Myeloge... | Therapy for Tar... Wait-List Contr... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia in Japan | NCT01464411 | Leukemia, Myelo... Myelogenous Leu... | 20 Months - | Kanto CML Study Group | ||
| Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia | NCT02709083 | Chronic Myeloge... Chronic Myeloid... Leukemia | Dasatinib Imatinib Mesyla... Nilotinib | 17 Years - | Emory University | |
| Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) | NCT00519090 | Myelogenous Leu... | Imatinib Nilotinib (AMN1... | 18 Years - | Novartis | |
| AHN-12 Biodistribution in Advanced Leukemia | NCT01207076 | Acute Myelogeno... Myelodysplastic... Acute Lymphobla... Chronic Myeloge... | 90Y-AHN-12 | 12 Years - | Masonic Cancer Center, University of Minnesota | |
| Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy | NCT00990587 | Hematologic Mal... Acute Lymphocyt... Chronic Lymphoc... Myelodysplasia Acute Myeloid L... Chronic Myeloge... Hodgkin's Disea... | Ciclopirox Olam... | 18 Years - | University Health Network, Toronto | |
| A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED) | NCT00500006 | Chronic Myeloge... Leukemia, Lymph... | MK0457 dasatinib | 18 Years - | Merck Sharp & Dohme LLC | |
| Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases | NCT00376519 | Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... Secondary Myelo... | cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... Treg cell infus... umbilical cord ... total-body irra... | 18 Years - 45 Years | Masonic Cancer Center, University of Minnesota | |
| Study Evaluating SKI-606 (Bosutinib) In Japanese Subjects With Philadelphia Chromosome Positive Leukemias | NCT00811070 | Chronic Myeloge... | SKI-606 (Bosuti... | 20 Years - 74 Years | Pfizer | |
| Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs | NCT03106779 | Chronic Myeloge... | Asciminib Bosutinib | 18 Years - | Novartis | |
| Treg Cells for AGVHD in Non-myeloablative UCB Transplant | NCT02118311 | Hematologic Mal... | T Regulatory ce... Fludarabine Cyclophosphamid... Total Body Irra... | 18 Years - 69 Years | Masonic Cancer Center, University of Minnesota | |
| Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase) | NCT00237120 | Chronic Myeloge... | Imatinib | 15 Years - 74 Years | Novartis | |
| Safety and Tolerability of HSC835 in Patients With Hematological Malignancies | NCT01474681 | Acute Myelocyti... Acute Lymphocyt... Chronic Myeloge... Myelodysplastic... Chronic Lymphoc... Marginal Zone L... Follicular Lymp... Large-cell Lymp... Lymphoblastic L... Burkitt's Lymph... High Grade Lymp... Mantle-cell Lym... Lymphoplasmacyt... | HSC835 | 10 Years - 55 Years | Novartis | |
| Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers | NCT00089596 | Acute Lymphocyt... Acute Myeloid L... Myelodysplastic... Non-Hodgkin Lym... Chronic Myeloge... | Expansion of um... | 12 Years - 60 Years | ViaCell | |
| Stem Cell (Modified Bone Marrow) Transplantation in HIV-Infected Patients With Blood Cancer | NCT00005785 | Hematologic Neo... HIV Infection | GCSF Mobilized ... | - | National Institutes of Health Clinical Center (CC) | |
| Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant | NCT00571662 | Acute Myelogeno... Acute Lymphocyt... Chronic Myeloge... Chronic Lymphoc... Myelodysplastic... Multiple Myelom... Non-Hodgkins Ly... Hodgkins Diseas... Peripheral T-ce... | Pentostatin Total-body irra... Cyclosporine A ... Mycophenolate M... G-CSF | 19 Years - 75 Years | University of Nebraska | |
| Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow | NCT00003838 | Myeloproliferat... Acute Myelogeno... Chronic Myeloge... Myelodysplastic... Acute Lymphobla... | T-cell replete ... Methotrexate Cyclosporine G-CSF | 2 Years - 80 Years | National Institutes of Health Clinical Center (CC) | |
| Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant | NCT01244906 | Hematologic Neo... | Allogeneic Hema... | 18 Years - 75 Years | Northside Hospital, Inc. | |
| Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan | NCT00337454 | Chronic Myeloge... | Dasatinib Dasatinib Dasatinib Dasatinib Dasatinib Dasatinib | 20 Years - 75 Years | Bristol-Myers Squibb | |
| Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients | NCT00499889 | Leukemia | Imatinib Mesyla... Fludarabine (Fl... Busulfan Antithymocyte G... Tacrolimus Methotrexate Donor lymphocyt... Stem Cell Trans... | - 70 Years | M.D. Anderson Cancer Center | |
| An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia | NCT00171249 | Philadelphia Po... Acute Lymphobla... Acute Myeloid L... | STI571 400 mg STI571 600 mg | 18 Years - | Novartis | |
| A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor | NCT01696461 | Related Donors ... Acute Myelogeno... Acute Lymphobla... Myelodysplastic... Chronic Myeloge... Non-Hodgkin's L... Hodgkin's Disea... Chronic Lymphoc... | Plerixafor | 18 Years - 65 Years | Center for International Blood and Marrow Transplant Research | |
| Study of Blood and Bone Marrow Samples in Patients With Chronic Myelogenous Leukemia Enrolled on a CALGB Clinical Trial | NCT01004640 | Leukemia | DNA analysis Southern blotti... cytogenetic ana... polymerase chai... | - | Alliance for Clinical Trials in Oncology | |
| Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia | NCT00333840 | Chronic Myeloge... | imatinib mesila... interferon-alph... cytarabine (ARA... | 18 Years - 70 Years | Novartis | |
| Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia | NCT03625388 | Chronic Myeloge... | Dasatinib | 18 Years - | Hikma Pharmaceuticals LLC | |
| Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies | NCT00514722 | Acute Myeloid L... Myelodysplasia Acute Lymphobla... Chronic Myeloge... Multiple Myelom... Lymphoma, Large... Lymphoma, Mantl... Lymphoma, T-Cel... T-NK Cell Lymph... Hodgkin Disease | umbilical cord ... | 18 Years - 55 Years | University of California, San Francisco | |
| Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies | NCT02743351 | Hematologic Mal... Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Chronic Myeloge... Acute Graft-ver... | ProTmune Control Arm | 18 Years - | Fate Therapeutics | |
| Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis | NCT02593123 | Hodgkin's Lymph... Lymphoid Leukem... Lymphoma Leukemia Myeloma Acute Lymphocyt... Non Hodgkin Lym... Chronic Lymphoc... Multiple Myelom... Chronic Myeloge... Myelodysplastic... Recurrent Acute... Recurrent Hodgk... Recurrent Non-H... Recurrent Plasm... Recurrent Chron... Recurrent Chron... Acute Myelogeno... | mycophenolate m... Sargramostim Filgrastim | 18 Years - 74 Years | Virginia Commonwealth University | |
| CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation | NCT00038818 | Chronic Myeloge... Multiple Myelom... Non Hodgkin's L... Hodgkin's Disea... Chronic Lymphoc... | CD8 Depleted Do... | - | M.D. Anderson Cancer Center | |
| Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | NCT03314974 | Acute Leukemia Acute Myeloid L... Acute Lymphobla... Lymphoma Chronic Myeloge... Plasma Cell Leu... Myeloproliferat... Myelofibrosis Myelodysplasia Refractory Anem... High Risk Anemi... Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Diffuse Large C... Lymphoblastic L... Burkitt Lymphom... High Grade Non-... Multiple Myelom... Juvenile Myelom... Biphenotypic/Un... MRD Positive Le... Natural Killer ... Acquired Bone M... | HSCT with TBI R... HSCT with Non-T... | - 60 Years | Masonic Cancer Center, University of Minnesota | |
| Effect of Imatinib on Bone Metabolism in Patients With Chronic Myelogenous Leukemia or Gastrointestinal Stromal Tumors | NCT00580281 | Gastric Cancer Leukemia Chronic Myeloge... | blood test, uri... | - | Memorial Sloan Kettering Cancer Center | |
| Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS | NCT00334074 | Acute Myelogeno... Myelodysplastic... Chronic Myeloge... | Clofarabine and... | 18 Years - 85 Years | Baylor Research Institute | |
| Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission | NCT01901666 | Chronic Myeloge... Short Stature | Growth Hormone | - | PIMERIndia | |
| Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy | NCT04014764 | Acute Myelogeno... Multiple Myelom... Myelodysplastic... Lymphoma Acute Lymphobla... Chronic Myeloge... Myeloproliferat... | This is a non-i... | 18 Years - | Notable Labs | |
| Prophylactic White Cell Transfusions Versus Therapeutic White Cell Transfusions in Patients With Leukemia | NCT01204788 | Leukemia | Prophylactic Wh... Therapeutic Whi... | 2 Years - | M.D. Anderson Cancer Center | |
| Autologous Stem Cell Transplants for Chronic Myelogenous Leukemia | NCT00446173 | Leukemia | Busulfan Cyclophosphamid... G-CSF GM-CSF | 21 Years - 65 Years | M.D. Anderson Cancer Center | |
| Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) | NCT00406393 | Leukemia, Myelo... Leukemia, Lymph... Leukemia, Myelo... Myelodysplastic... | Tacrolimus Methotrexate Sirolimus | 2 Years - 60 Years | Medical College of Wisconsin | |
| An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia | NCT00171249 | Philadelphia Po... Acute Lymphobla... Acute Myeloid L... | STI571 400 mg STI571 600 mg | 18 Years - | Novartis | |
| Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients | NCT00493181 | Leukemia Chronic Myeloge... Chronic Myeloid... | Interleukin-11 ... | - | M.D. Anderson Cancer Center | |
| Autologous Transplantation for Chronic Myelogenous Leukemia | NCT01003054 | Chronic Myeloge... | Busulfan Cyclophosphamid... Imatinib Mesyla... Autologous Stem... | - 70 Years | M.D. Anderson Cancer Center | |
| Stem Cell Transplantation for Patients With Cancers of the Blood | NCT00467961 | CML (Chronic My... CLL (Chronic Ly... AML (Acute Myel... Acute Lymphocyt... MDS (Myelodyspl... | Miltenyi system | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants | NCT00378534 | Chronic Myeloge... Acute Myelogeno... Chronic Lymphoc... Acute Lymphobla... Myelodysplastic... | Miltenyi reagen... Fludarabine Cyclosporine Cyclophosphamid... FILGRASTIM (G-C... | 10 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases | NCT02145039 | Acute Leukemias Burkitt's Lymph... Chronic Myeloge... | Fludarabine Cyclophosphamid... Total Body Irra... Haploidentical ... | - 74 Years | Masonic Cancer Center, University of Minnesota | |
| T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer | NCT00602693 | Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic... | umbilical cord ... Allopurinol fludarabine pho... Cyclophosphamid... Total body irra... Treg infusion Sirolimus | 18 Years - 75 Years | Masonic Cancer Center, University of Minnesota | |
| Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell | NCT01660607 | Myeloid Leukemi... Acute Myelogeno... Myelodysplastic... Lymphoma, Non-H... Acute Lymphobla... Myeloproliferat... Acute Myeloid L... Acute Leukemia Chronic Myeloge... | Conventional T ... | 13 Years - 60 Years | Stanford University | |
| Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant | NCT00413270 | Chronic Myeloge... | nilotinib | 18 Years - | Novartis | |
| PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron | NCT00037882 | Leukemia, Myelo... | PEG-Intron | - | M.D. Anderson Cancer Center | |
| Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants | NCT00378534 | Chronic Myeloge... Acute Myelogeno... Chronic Lymphoc... Acute Lymphobla... Myelodysplastic... | Miltenyi reagen... Fludarabine Cyclosporine Cyclophosphamid... FILGRASTIM (G-C... | 10 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML) | NCT00050531 | Leukemia, Myelo... | Gleevec Peg-alpha inter... Sargramostim (G... | 18 Years - | M.D. Anderson Cancer Center | |
| Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies | NCT00270881 | Acute Myelogeno... Acute Lymphobla... Chronic Myeloge... Myelodysplastic... | Cord blood tran... TBI cyclophosphamid... cytarabine | 20 Years - 55 Years | Keio University | |
| A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies | NCT00109707 | Chronic Myeloge... Acute Lymphobla... Hypereosinophil... Systemic Mastoc... | Nilotinib | 18 Years - | Novartis | |
| StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies | NCT02765997 | Acute Myeloid L... Acute Lymphocyt... Chronic Myeloge... Myelodysplasia | Unmanipulated U... SR-1 UCB | 2 Years - 35 Years | Masonic Cancer Center, University of Minnesota | |
| Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation | NCT01634217 | Acute Myelogeno... Acute Lymphocyt... Chronic Myeloge... Non-Hodgkin Lym... Hodgkin Lymphom... Chronic Lymphoc... Multiple Myelom... Myelodysplastic... | iTreg | 18 Years - 75 Years | Masonic Cancer Center, University of Minnesota | |
| A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL | NCT00384228 | Chronic Myeloge... Acute Lymphobla... | Nilotinib | 20 Years - | Novartis | |
| Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy | NCT00990587 | Hematologic Mal... Acute Lymphocyt... Chronic Lymphoc... Myelodysplasia Acute Myeloid L... Chronic Myeloge... Hodgkin's Disea... | Ciclopirox Olam... | 18 Years - | University Health Network, Toronto | |
| PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP | NCT00088231 | Acute Myelogeno... Agnogenic Myelo... Chronic Myeloge... | Imatinib Mesyla... PTK 787 (vatala... | 15 Years - | M.D. Anderson Cancer Center | |
| Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia | NCT03216070 | Chronic Myeloge... | Dasatinib 50 MG | 16 Years - | Hospital Universitario Dr. Jose E. Gonzalez | |
| Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer | NCT00975975 | Acute Myelogeno... Acute Lymphocyt... Chronic Myeloge... Chronic Lymphoc... Myelodysplasia Non-Hodgkin's L... Hodgkin's Disea... Multiple Myelom... Myelofibrosis Anemia, Aplasti... Hemoglobinuria,... | Basiliximab | 18 Years - | Indiana University | |
| Study Evaluating SKI-606 (Bosutinib) In Japanese Subjects With Philadelphia Chromosome Positive Leukemias | NCT00811070 | Chronic Myeloge... | SKI-606 (Bosuti... | 20 Years - 74 Years | Pfizer | |
| Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors | NCT04795427 | Leukemia, Chron... | asciminib best available ... | 18 Years - | Novartis | |
| Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C | NCT00038649 | Myelogenous Leu... | Gleevec | 15 Years - | M.D. Anderson Cancer Center | |
| Asciminib Roll-over Study | NCT04877522 | Chronic Myeloge... Leukemia, Myelo... | Asciminib singl... Asciminib Imatinib Nilotinib Bosutinib Dasatinib | 18 Years - | Novartis | |
| Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies | NCT02566395 | Acute Lymphobla... Acute Myelogeno... Myelodysplastic... Chronic Myeloge... Non-Hodgkin Lym... Hodgkin Lymphom... | Radiation Cyclophosphamid... Donor Lymphocyt... Haploidentical ... | 2 Years - 21 Years | Northwell Health | |
| TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients | NCT00415909 | Chronic Myeloge... | Imatinib Mesyla... TALL-104 cells | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP Patients | NCT02511340 | Chronic Myeloge... | Flumatinib mesy... | 18 Years - 75 Years | Jiangsu Hansoh Pharmaceutical Co., Ltd. | |
| Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated Lymphocytes | NCT00038870 | Acute Myelogeno... Chronic Myeloge... | Dendritic Cell ... | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| FTS Study in Patients With Advanced Hematologic Malignancies | NCT00867230 | Myelodysplastic... Leukemia | FTS | 18 Years - | M.D. Anderson Cancer Center | |
| Safety And Efficacy Of Bosutinib | NCT02501330 | Chronic Myeloge... | Bosutinib | 0 Years - | Pfizer | |
| Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | NCT03314974 | Acute Leukemia Acute Myeloid L... Acute Lymphobla... Lymphoma Chronic Myeloge... Plasma Cell Leu... Myeloproliferat... Myelofibrosis Myelodysplasia Refractory Anem... High Risk Anemi... Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Diffuse Large C... Lymphoblastic L... Burkitt Lymphom... High Grade Non-... Multiple Myelom... Juvenile Myelom... Biphenotypic/Un... MRD Positive Le... Natural Killer ... Acquired Bone M... | HSCT with TBI R... HSCT with Non-T... | - 60 Years | Masonic Cancer Center, University of Minnesota | |
| Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR | NCT01611298 | Acute Lymphobla... Acute Myelogeno... Chronic Myeloge... Myelodysplastic... Hodgkin Lymphom... Non-Hodgkin Lym... | Tetanus | 3 Years - 70 Years | Baylor College of Medicine | |
| Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR) | NCT00760877 | CHRONIC MYELOGE... | Nilotinib Imatinib | 18 Years - | Novartis | |
| Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) | NCT03578367 | CML Chronic Myeloge... Leukemia, Myelo... Hematologic Dis... | Asciminib add-o... Imatinib Nilotinib Asciminib singl... | 18 Years - | Novartis | |
| Analysis of Genetic Factors Related to Predisposition and Prognosis of Hematological Malignancies in Israel | NCT00159003 | Acute Myeloid L... Chronic Lymphoc... Chronic Myeloge... | 18 Years - | Hadassah Medical Organization |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
